Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer.
A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Chimerix is selling global rights to smallpox drug Tembexa, the biotech’s only FDA-approved product, as a way to fund clinical development of a therapy in pivotal testing for a rare type of brain cancer. The deal marks Chimerix’s nearly complete departure from the antiviral work that defined the company for most of its history.
Almost no new therapies have succeeded in extending patient survival in GBM in the last 20 years, and the field is littered with drugs that have failed despite promising early data. But researchers soldier on with new molecular targets and therapeutic modalities.
The company said Thursday morning that its study failed to meet its primary endpoint in high-grade gliomas. Shares of the company fell more than 80 percent on the Nasdaq.
The drug was being tested in combination with radiation therapy among newly diagnosed patients with glioblastoma, a notoriously difficult-to-treat and invariably fatal disease.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Tempe, Arizona-based GT Medical Technologies has developed the GammaTile, a surgically targeted brachytherapy technology for the treatment of recurrent brain tumors.
Simply put, working together is better than working alone. At MedCity CONVERGE, three panelists discussed an organization based on the idea of collaboration: the Philadelphia Coalition for a Cure, which is seeking to put an end to brain cancer.
On Wednesday, the same day McCain's brain cancer diagnosis was publicly revealed, a paper was published in the journal Science Translational Medicine discussing a CAR-T approach to treating glioblastoma.
At ASCO 2016, Cleveland Clinic researchers examined the impact of the number of brain metastases on overall survival for two common cancer types: Non-small cell lung cancer and gastroesophageal cancer.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Just this month, the company received orphan drug designation in both the European Union and America for treating glioblastoma.
Celldex's brain cancer vaccine improves survival rates and, importantly, improves quality of life, according to new topline results just released by the company.
Palo Alto startup Orbus Therapeutics just reeled in $32.5 million to bring eflornithine, an already-approved drug for hirsutism and sleeping sickness, into Phase 3 trials for brain cancer.
Former President Jimmy Carter has been informed that cancer has now spread to his brain.
Brain tumors are usually treated with an intense course of cancer’s Big Three: Surgery, radiation and heavy chemotherapy. Medical device startup Novocure is adding a new treatment option into the mix: Electrofield therapy, in which alternating electric fields shut down cellular division – curbing the growth of cancer. It’s called Optune. And it seems to be wildly […]